Conversely, in the adult POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) study of allogeneic versus autologous BM‐MSCs for ischemic cardiomyopathy, patients receiving autologous MSCs experienced more frequent treatment‐emergent serious adverse events, although this did not reach statistical significance, but also significant improvement on functional and quality‐of‐life measures 97 .
← all excerpts
Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements.
1
—
—